Needham & Company
-
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
-
Nurix Therapeutics (NRIX) Announces Proposed $125M Share Offering
-
Nurix Therapeutics Announces Proposed Public Offering
-
Nurix Therapeutics to Participate in Upcoming Investor Conferences
-
Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
-
Nurix (NRIX) PT Lowered to $32 at Needham & Company
-
Needham & Company Reiterates Nurix (NRIX) at Buy with $48 Price Target
-
Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
-
Nurix (NRIX) Reiterated at Buy at Needham & Company, "Expect Value Creation in 2022 Across Nurix Pipeline"
-
Nurix (NRIX) PT Raised to $48 at Needham & Company
-
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
-
Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Nurix Therapeutics (NRIX) Prices 4.5M Share Upsized Common Offering at $31/Sh
-
Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
-
Nurix Therapeutics (NRIX) Announces Launch of Proposed Public Offering of Common Stock
-
Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock
-
Companies with NDRs 10/20
-
Companies with NDRs 10/19
-
Nurix Therapeutics (NRIX) IPO Opens Lower
-
Nurix Therapeutics Inc. (NRIX) Prices 11M Share IPO at $19/Sh
-
Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering

